MNOV RSI Chart
Last 7 days
-6.5%
Last 90 days
5.1%
Trailing 12 Months
-32.6%
Historical Charts for Stock Metrics
Year | Q1 | Q2 | Q3 | Q4 |
---|---|---|---|---|
2024 | 1.7M | 0 | 0 | 0 |
2023 | 1.3M | 1.6M | 1.8M | 1.8M |
2022 | 3.2M | 2.4M | 1.6M | 809.7K |
2021 | 7.4M | 8.7M | 9.9M | 4.0M |
2020 | 6.6M | 7.0M | 6.6M | 6.2M |
2019 | 1.7M | 1.7M | 1.8M | 6.5M |
2018 | 7.8M | 5.7M | 3.6M | 1.5M |
2017 | 2.6M | 5.0M | 7.5M | 9.9M |
2016 | 495.5K | 383.5K | 271.5K | 159.5K |
2015 | 2.9M | 2.1M | 1.4M | 607.5K |
2014 | 5.4M | 4.8M | 4.3M | 3.7M |
2013 | 3.4M | 0 | 0 | 6.0M |
2012 | 0 | 0 | 0 | 802.6K |
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
Nov 28, 2022 | nagao hideki | sold | -15,196 | 2.25 | -6,754 | - |
Nov 22, 2022 | nagao hideki | sold | -464 | 2.13 | -218 | - |
Nov 21, 2022 | nagao hideki | sold | -11,695 | 2.18 | -5,365 | - |
Nov 17, 2022 | nagao hideki | sold | -673 | 2.18 | -309 | - |
Aug 23, 2021 | matsuda kazuko | acquired | 138,000 | 2.3 | 60,000 | chief medical officer |
Jul 09, 2021 | iwaki yuichi | acquired | 100,541 | 2.54 | 39,583 | president and ceo |
Jun 24, 2021 | matsuda kazuko | acquired | 256,622 | 2.49623 | 102,804 | chief medical officer |
May 19, 2021 | obrien geoffrey | acquired | 109,122 | 2.5191 | 43,318 | vice president |
Mar 11, 2021 | nagao hideki | sold | -17,419 | 7.4 | -2,354 | - |
Feb 25, 2021 | iwaki yuichi | acquired | 212,175 | 2.46 | 86,250 | president and ceo |
Which funds bought or sold MNOV recently?
View All DetailsDatesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
May 16, 2024 | JANE STREET GROUP, LLC | reduced | -19.39 | -4,752 | 16,766 | -% |
May 15, 2024 | NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO | unchanged | - | -16.00 | 442 | -% |
May 15, 2024 | CITADEL ADVISORS LLC | new | - | 37,949 | 37,949 | -% |
May 15, 2024 | GOLDMAN SACHS GROUP INC | sold off | -100 | -16,416 | - | -% |
May 15, 2024 | Royal Bank of Canada | reduced | -55.24 | - | 1,000 | -% |
May 15, 2024 | BRIDGEWAY CAPITAL MANAGEMENT, LLC | unchanged | - | -7,258 | 210,463 | -% |
May 15, 2024 | MILLENNIUM MANAGEMENT LLC | reduced | -17.43 | -11,015 | 43,570 | -% |
May 15, 2024 | Tower Research Capital LLC (TRC) | added | 30.15 | 3,149 | 15,355 | -% |
May 15, 2024 | Essex Woodlands Management, Inc. | unchanged | - | -55,298 | 1,603,610 | 0.47% |
May 15, 2024 | Squarepoint Ops LLC | reduced | -1.94 | -1,184 | 21,541 | -% |
Unveiling MediciNova Inc's Major ShareHolders
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Peers (Alternatives to MediciNova Inc)
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
MRNA | 50.9B | 6.8B | -8.53 | 7.44 | ||||
HILS | 22.5B | 216.3K | -2.5K | 104.0K | ||||
ALNY | 18.9B | 2.0B | -56.9 | 9.43 | ||||
BMRN | 14.7B | 2.5B | 71.65 | 5.96 | ||||
INCY | 12.8B | 3.8B | 17.2 | 3.4 | ||||
MID-CAP | ||||||||
BBIO | 5.6B | 107.9M | -10.31 | 48.09 | ||||
APLS | 5.0B | 524.1M | -12.02 | 9.57 | ||||
AXSM | 3.6B | 251.0M | -12.28 | 14.5 | ||||
ARWR | 3.1B | 240.7M | -6.53 | 12.77 | ||||
ACAD | 2.4B | 813.8M | -1.4K | 3 | ||||
SMALL-CAP | ||||||||
CPRX | 1.9B | 411.3M | 29.91 | 4.73 | ||||
NVAX | 1.8B | 996.6M | -4.58 | 1.83 | ||||
CRBP | 480.9M | 881.7K | -14.25 | 481.06 | ||||
INO | 310.9M | 4.9M | -2.49 | 63.89 | ||||
IBIO | 17.1M | 2.1M | -0.74 | 7.61 |
MediciNova Inc News
Income Statement (Quarterly) | ||||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 |
Revenue | -8.9% | 397,510 | 436,265 | 437,934 | 451,420 | 509,046 | 427,304 | 253,755 | 91,275 | 45,638 | - | 37,500 | - | 4,000,000 | 5,863,904 | 3,313,194 | 762,483 | 412,692 | 5,569,048 | 288,643 | 307,574 | 304,245 |
Operating Expenses | 25.9% | 3,135,993 | 2,490,104 | 2,146,888 | 3,300,030 | 2,963,243 | 3,231,235 | 3,897,467 | 4,089,935 | 3,410,012 | 2,102,831 | 3,639,439 | 4,309,513 | 4,201,529 | 3,013,442 | 3,730,016 | 4,510,366 | 2,924,499 | 2,224,132 | 2,645,565 | 4,182,021 | 4,979,359 |
S&GA Expenses | -100.0% | - | 839,326 | 1,352,182 | 1,564,295 | 1,486,567 | 1,218,611 | 1,443,264 | 1,524,966 | 1,298,016 | 325,819 | 1,550,821 | 1,782,390 | 2,056,255 | 1,216,265 | 1,492,139 | 2,311,330 | 1,673,754 | 395,295 | 1,494,750 | 2,716,509 | 3,345,481 |
R&D Expenses | - | 1,700,000 | - | - | - | 1,400,000 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EBITDA Margin | -6.5% | -4.96 | -4.66 | -7.69 | -8.56 | -10.96 | -17.35 | -6.25 | -4.17 | -3.13 | -2.50 | -1.40 | -1.60 | - | - | - | - | - | - | - | - | - |
EBT Margin | -6.5% | -4.97 | -4.67 | -7.70 | -8.57 | -10.98 | -17.37 | -6.27 | -4.18 | -3.14 | -2.51 | -1.40 | -1.60 | - | - | - | - | - | - | - | - | - |
Net Income | -33.8% | -2,754,518 | -2,059,085 | -723,107 | -2,871,820 | -2,917,504 | -3,001,484 | -3,652,184 | -4,028,998 | -3,386,417 | -2,083,145 | -3,579,167 | -4,284,141 | -187,799 | -2,985,289 | -3,703,820 | -4,451,229 | -2,713,559 | -1,984,088 | -2,378,504 | -3,881,876 | -4,697,190 |
Net Income Margin | -4.4% | -4.88 | -4.67 | -5.21 | -7.58 | -10.61 | -17.38 | -8.13 | -5.40 | -4.13 | -2.51 | -1.11 | -1.29 | - | - | - | - | - | - | - | - | - |
Free Cashflow | -675.1% | -3,868,226 | -499,038 | -1,374,293 | -2,383,016 | -3,177,413 | -4,007,044 | -2,720,151 | -2,455,968 | -3,728,400 | -3,638,966 | -3,018,561 | 1,094,238 | - | - | - | - | - | - | - | - | - |
Balance Sheet | ||||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 |
Assets | -5.1% | 63.00 | 66.00 | 68.00 | 69.00 | 71.00 | 74.00 | 78.00 | 81.00 | 84.00 | 87.00 | 92.00 | 94.00 | 96.00 | 75.00 | 77.00 | 76.00 | 77.00 | 79.00 | 78.00 | 77.00 | 79.00 |
Current Assets | -6.5% | 48.00 | 51.00 | 53.00 | 54.00 | 56.00 | 59.00 | 53.00 | 66.00 | 69.00 | 72.00 | 76.00 | 79.00 | 81.00 | 61.00 | 63.00 | 61.00 | 62.00 | 64.00 | 63.00 | 62.00 | 64.00 |
Cash Equivalents | -7.6% | 47.00 | 51.00 | 52.00 | 53.00 | 55.00 | 19.00 | 53.00 | 65.00 | 68.00 | 71.00 | 75.00 | 78.00 | 76.00 | 60.00 | 62.00 | 60.00 | 61.00 | 64.00 | 63.00 | 62.00 | 63.00 |
Net PPE | -11.8% | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Goodwill | 0% | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
Liabilities | -21.3% | 3.00 | 4.00 | 3.00 | 4.00 | 3.00 | 4.00 | 5.00 | 5.00 | 4.00 | 4.00 | 5.00 | 4.00 | 4.00 | 4.00 | 4.00 | 5.00 | 4.00 | 4.00 | 4.00 | 4.00 | 4.00 |
Current Liabilities | -23.4% | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 5.00 | 4.00 | 3.00 | 3.00 | 4.00 | 2.00 | 2.00 | 2.00 | 2.00 | 3.00 | 2.00 | 2.00 | 2.00 | 2.00 | 1.00 |
Shareholder's Equity | -4.1% | 60.00 | 62.00 | 65.00 | 65.00 | 68.00 | 70.00 | 73.00 | 77.00 | 80.00 | 84.00 | 86.00 | 89.00 | 92.00 | 71.00 | 74.00 | 71.00 | 73.00 | 75.00 | 74.00 | 73.00 | 75.00 |
Retained Earnings | -0.7% | -418 | -415 | -413 | -412 | -410 | -407 | -404 | -400 | -396 | -393 | -390 | -387 | -383 | -382 | -379 | -376 | -371 | -369 | -367 | -364 | -360 |
Additional Paid-In Capital | 0.0% | 478 | 478 | 478 | 478 | 478 | 477 | 477 | 477 | 477 | 477 | 478 | 477 | 476 | 454 | 454 | 447 | 445 | 444 | 441 | 438 | 436 |
Shares Outstanding | 0% | 49.00 | 49.00 | 49.00 | 49.00 | 49.00 | 49.00 | 49.00 | 49.00 | 49.00 | 49.00 | 49.00 | 48.00 | - | - | - | - | - | - | - | - | - |
Float | - | - | - | - | 109 | - | - | - | 118 | - | - | - | 197 | - | - | - | 227 | - | - | - | 393 | - |
Cashflow (Quarterly) | ||||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 |
Cashflow From Operations | -675.1% | -3,868 | -499 | -1,371 | -2,383 | -3,177 | -4,007 | -2,720 | -2,455 | -3,728 | -3,638 | -3,015 | 1,127 | -3,853 | -1,949 | -3,908 | -2,090 | -2,878 | -2,404 | -2,039 | -1,652 | -3,029 |
Share Based Compensation | 190.7% | 215 | -237 | 219 | 326 | 403 | 129 | 158 | 275 | 81.00 | -756 | 579 | 756 | 1,140 | 398 | 1,034 | 1,147 | 596 | -803 | 374 | 1,843 | 2,700 |
Cashflow From Investing | -100.0% | - | 22* | -2.74 | -18.58 | 39,929 | -30,005 | - | - | - | - | -2.94 | - | - | -32.70 | -1.19 | -10* | -2.59 | -7.26 | - | -2.06 | -1.95 |
Cashflow From Financing | - | - | - | - | - | - | - | - | - | - | 39.00 | 250 | 390 | 20,100 | 359 | 5,127 | 1,201 | 419 | 3,331 | 3,175 | 180 | 3,929 |
Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($) | 3 Months Ended | |
---|---|---|
Mar. 31, 2024 | Mar. 31, 2023 | |
Operating expenses: | ||
Research, development and patents | $ 1,781,869 | $ 1,476,676 |
General and administrative | 1,354,124 | 1,486,567 |
Total operating expenses | 3,135,993 | 2,963,243 |
Operating loss | (3,135,993) | (2,963,243) |
Interest income | 397,510 | 509,046 |
Other expense | (16,035) | (463,307) |
Net loss | $ (2,754,518) | $ (2,917,504) |
Basic net loss per common share | $ (0.06) | $ (0.06) |
Diluted net loss per common share | $ (0.06) | $ (0.06) |
Shares used to compute basic net loss per common share | 49,046,246 | 49,046,246 |
Shares used to compute diluted net loss per common share | 49,046,246 | 49,046,246 |
Net loss | $ (2,754,518) | $ (2,917,504) |
Other comprehensive loss, net of tax: | ||
Foreign currency translation adjustments | (8,892) | (1,542) |
Comprehensive loss | $ (2,763,410) | $ (2,919,046) |
Condensed Consolidated Balance Sheets - USD ($) | Mar. 31, 2024 | Dec. 31, 2023 |
---|---|---|
Current assets: | ||
Cash and cash equivalents | $ 47,138,799 | $ 50,999,442 |
Prepaid expenses and other current assets | 724,796 | 174,938 |
Total current assets | 47,863,595 | 51,174,380 |
Goodwill | 9,600,240 | 9,600,240 |
In-process research and development | 4,800,000 | 4,800,000 |
Property and equipment, net | 40,384 | 45,800 |
Right-of-use asset | 519,307 | 575,406 |
Other non-current assets | 70,391 | 74,151 |
Total assets | 62,893,917 | 66,269,977 |
Current liabilities: | ||
Accounts payable | 804,764 | 1,003,937 |
Accrued liabilities and other current liabilities | 1,487,845 | 2,059,238 |
Operating lease liability | 217,887 | 215,926 |
Total current liabilities | 2,510,496 | 3,279,101 |
Deferred tax liability | 201,792 | 201,792 |
Other non-current liabilities | 351,185 | 410,660 |
Total liabilities | 3,063,473 | 3,891,553 |
Commitments and contingencies (Note 4) | ||
Stockholders’ equity: | ||
Common stock, $0.001 par value; 100,000,000 shares authorized at March 31, 2024 and December 31, 2023; 49,046,246 and 49,046,246 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively | 49,046 | 49,046 |
Additional paid-in capital | 478,364,591 | 478,149,161 |
Accumulated other comprehensive loss | (126,982) | (118,090) |
Accumulated deficit | (418,456,211) | (415,701,693) |
Total stockholders’ equity | 59,830,444 | 62,378,424 |
Total liabilities and stockholders' equity | $ 62,893,917 | $ 66,269,977 |